Base de dados : MEDLINE
Pesquisa : D02.092.782.200 [Categoria DeCS]
Referências encontradas : 392 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 40 ir para página                         

  1 / 392 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27678425
[Au] Autor:Zhao XQ; Phan BA; Davis J; Isquith D; Dowdy AA; Boltz S; Neradilek M; Monick EA; Brockenbrough A; Hus-Frechette EE; Albers JJ; Brown BG
[Ad] Endereço:Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: xueqiao@uw.edu.
[Ti] Título:Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study.
[So] Source:J Clin Lipidol;10(5):1091-7, 2016 Sep-Oct.
[Is] ISSN:1933-2874
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cardiovascular disease (CVD) begins early in life and is associated with both the number of risk factors present and length of exposure to these risk factors including hyperlipidemia. OBJECTIVES: The clinical benefit of intensive lipid therapy over 25 years was investigated in the Familial Atherosclerosis Treatment Study-Observational Study. METHODS: Of 175 coronary artery disease subjects with mean low-density lipoprotein cholesterol (LDL-C) of 191 mg/dL and mean age of 50 years, who completed the randomized and placebo-controlled Familial Atherosclerosis Treatment Study, 100 chose receiving lipid management by their physicians (usual care [UC]) and 75 elected to receive an intensive treatment [IT] for lipid management with lovastatin (40 mg/d), niacin (2.5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40-80 mg/d) and niacin from 2005 to 2006 and by triple therapy of ezetimibe 10 mg and simvastatin 40 to 80 mg/d plus niacin during 2007 to 2012. Deaths from CVD, non-CVD, and any cause were compared between UC and IT using Cox proportional hazards model. RESULTS: UC and IT groups were similar in risk factors with the exception that IT had more severe coronary artery disease. Mean LDL-C levels were 167 mg/dL from 1988 to 2004, 97 from 2005 to 2006, and 96 from 2007 to 2012 in surviving subjects receiving UC. IT lowered LDL-C to 119, 97, and 83 mg/dL in the 3 periods, respectively. Compared with UC, IT significantly reduced total mortality (11.1 vs 26.3 per 1000 person years [PY], hazard ratio [HR] = 0.45, 95% confidence interval [CI]: 0.26-0.77, P = .003) and CVD mortality (10.6 vs 27.7 per 1000 PY, HR = 0.34, 95% CI: 0.15-0.80, P = .009). The non-CVD mortality was also reduced but was not of statistical significance (6.8 vs 12.7 per 1000 PY, HR = 0.55, 95% CI: 0.27-1.14, P = .11). CONCLUSIONS: Long-term intensive lipid therapy significantly reduced total and cardiovascular mortality in Familial Atherosclerosis Treatment Study-Observational Study. These results support the importance of lifetime risk management to improve long-term outcome.
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Aterosclerose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Aterosclerose/mortalidade
Azetidinas/uso terapêutico
LDL-Colesterol/sangue
Ensaios Clínicos como Assunto
Colestipol/uso terapêutico
Doença da Artéria Coronariana/tratamento farmacológico
Doença da Artéria Coronariana/mortalidade
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Lovastatina/uso terapêutico
Masculino
Meia-Idade
Niacina/uso terapêutico
Modelos de Riscos Proporcionais
Sinvastatina/uso terapêutico
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Azetidines); 0 (Cholesterol, LDL); 0 (Triglycerides); 2679MF687A (Niacin); 9LHU78OQFD (Lovastatin); AGG2FN16EV (Simvastatin); K50N755924 (Colestipol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160929
[St] Status:MEDLINE


  2 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27191492
[Au] Autor:Morgan B
[Ti] Título:Drug development: A healthy pipeline.
[So] Source:Nature;533(7603):S116-7, 2016 05 19.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome do Intestino Irritável/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Benzimidazóis/uso terapêutico
Benzofuranos/uso terapêutico
Ácidos e Sais Biliares/metabolismo
Carbolinas/efeitos adversos
Cloridrato de Colesevelam/uso terapêutico
Colestipol/uso terapêutico
Modelos Animais de Doenças
Sistema Nervoso Entérico/fisiopatologia
Feminino
Seres Humanos
Imidazóis/uso terapêutico
Indóis/efeitos adversos
Síndrome do Intestino Irritável/complicações
Síndrome do Intestino Irritável/fisiopatologia
Loperamida/uso terapêutico
Lubiprostona/uso terapêutico
Masculino
Camundongos
Peptídeos Natriuréticos/uso terapêutico
Peptídeos/uso terapêutico
Fenilalanina/análogos & derivados
Fenilalanina/uso terapêutico
Receptores 5-HT3 de Serotonina/metabolismo
Receptores 5-HT4 de Serotonina/metabolismo
Rifamicinas/uso terapêutico
Serotonina/metabolismo
Antagonistas da Serotonina/uso terapêutico
Agonistas de Receptores de Serotonina/uso terapêutico
Dor Visceral/complicações
Dor Visceral/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzimidazoles); 0 (Benzofurans); 0 (Bile Acids and Salts); 0 (Carbolines); 0 (Imidazoles); 0 (Indoles); 0 (Natriuretic Peptides); 0 (Peptides); 0 (Receptors, Serotonin, 5-HT3); 0 (Rifamycins); 0 (Serotonin Antagonists); 0 (Serotonin Receptor Agonists); 0A09IUW5TP (prucalopride); 13Z9HTH115 (alosetron); 158165-40-3 (Receptors, Serotonin, 5-HT4); 333DO1RDJY (Serotonin); 458VC51857 (tegaserod); 45TPJ4MBQ1 (eluxadoline); 47E5O17Y3R (Phenylalanine); 6X9OC3H4II (Loperamide); 7662KG2R6K (Lubiprostone); 7IK8Z952OK (plecanatide); 7ZRO0SC54Y (ramosetron); K50N755924 (Colestipol); L36O5T016N (rifaximin); N0TXR0XR5X (linaclotide); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE
[do] DOI:10.1038/533S116a


  3 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26636406
[Au] Autor:Lin S; Sanders DS; Gleeson JT; Osborne C; Messham L; Kurien M
[Ad] Endereço:aDepartment of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust bDepartment of Infection and Immunity, Academic Unit of Gastroenterology, Medical School, University of Sheffield, Sheffield, UK.
[Ti] Título:Long-term outcomes in patients diagnosed with bile-acid diarrhoea.
[So] Source:Eur J Gastroenterol Hepatol;28(2):240-5, 2016 Feb.
[Is] ISSN:1473-5687
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Bile-acid diarrhoea (BAD) is a recognized cause of chronic diarrhoea; however, its detection remains suboptimal. Currently, there is a paucity of follow-up studies evaluating BAD. This work evaluates the natural history of BAD by examining individuals diagnosed with BAD [7 days of Se-homocholic acid taurine (SeHCAT) retention<10%] and determining the use of and response to bile-acid sequestrants (BAS). MATERIALS AND METHODS: Of the 515 patients, 40% (207/515) who underwent an SeHCAT test at Sheffield Teaching Hospitals (2001-2012) for chronic diarrhoea had BAD. Of the 207 (51%) patients, 107 were diagnosed between 2001 and 2009. In accordance with the guidelines, all of these patients were commenced on BAS. In March 2013, these individuals were reassessed either in the clinic or over the telephone as part of a local service evaluation project. Comparisons were made of both pretreatment and post-treatment variables using a Wilcoxon rank test. RESULTS: Of the 107 patients, 54% (58/107) were followed up, with a median time since diagnosis of 6 years. Among them, 38% were still using BAS at follow-up, with 28% using alternative antidiarrhoeals. The median stool frequency decreased from seven stools per day to three (P=0.0008) in those using BAS. The 34% of patients not receiving treatment had no change in their daily bowel frequency. The main reason for discontinuing treatment was poor tolerability of the BAS (colestyramine/colestipol). CONCLUSION: Our findings indicate that BAD is a chronic condition that best improves with BAS. Consideration should be given to therapeutic options that have a better tolerability profile.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Diarreia/etiologia
[Mh] Termos MeSH secundário: Resinas de Troca de Ânions/uso terapêutico
Antidiarreicos/uso terapêutico
Resina de Colestiramina/uso terapêutico
Colestipol/uso terapêutico
Defecação
Técnicas de Diagnóstico do Sistema Digestório
Diarreia/diagnóstico
Diarreia/tratamento farmacológico
Diarreia/metabolismo
Diarreia/fisiopatologia
Substituição de Medicamentos
Inglaterra
Hospitais de Ensino
Seres Humanos
Valor Preditivo dos Testes
Estudos Retrospectivos
Sequestrantes/uso terapêutico
Ácido Taurocólico/administração & dosagem
Ácido Taurocólico/análogos & derivados
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anion Exchange Resins); 0 (Antidiarrheals); 0 (Bile Acids and Salts); 0 (Sequestering Agents); 11041-12-6 (Cholestyramine Resin); 5E090O0G3Z (Taurocholic Acid); 75018-70-1 (23-seleno-25-homotaurocholic acid); K50N755924 (Colestipol)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151223
[Lr] Data última revisão:
151223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151205
[St] Status:MEDLINE
[do] DOI:10.1097/MEG.0000000000000541


  4 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25670355
[Au] Autor:Hemphill LC
[Ad] Endereço:Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: lhemphill@partners.org.
[Ti] Título:The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy.
[So] Source:J Clin Lipidol;9(1):11-3, 2015 Jan-Feb.
[Is] ISSN:1933-2874
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Aterosclerose/tratamento farmacológico
Colestipol/uso terapêutico
Niacina/uso terapêutico
[Mh] Termos MeSH secundário: Aterosclerose/diagnóstico por imagem
LDL-Colesterol/sangue
Ensaios Clínicos como Assunto
Seres Humanos
Radiografia
Resultado do Tratamento
Triglicerídeos/sangue
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Cholesterol, LDL); 0 (Triglycerides); 2679MF687A (Niacin); K50N755924 (Colestipol)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150212
[St] Status:MEDLINE


  5 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25557531
[Au] Autor:Hood CJ; Wolley MJ; Kam AL; Kendrik-Jones JC; Marshall MR
[Ad] Endereço:Department of Renal Medicine, Counties Manukau District Health Board, Shanghai, China; Faculty of Medical and Health Sciences, University of Auckland, Shanghai, China.
[Ti] Título:Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients.
[So] Source:Nephrology (Carlton);20(4):250-6, 2015 Apr.
[Is] ISSN:1440-1797
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Currently available calcium- and aluminium-based phosphate binders are dose limited because of potential toxicity, and newer proprietary phosphate binders are expensive. We examined phosphate-binding effects of the bile acid sequestrant colestipol, a non-proprietary drug that is in the same class as sevelamer. METHODS: The trial was an 8 week prospective feasibility study in stable hemodialysis patients using colestipol as the only phosphate binder, preceded and followed by a washout phase of all other phosphate binders. The primary study endpoint was weekly measurements of serum phosphate. Secondary endpoints were serum calcium, lipids and coagulation status. Analyses used random effects mixed models. RESULTS: Thirty patients were screened for participation of which 26 met criteria for treatment. At a mean dose of 8.8 g/24 h of colestipol by study end, serum phosphate dropped from 2.24 to 1.96 mmol/L (P < 0.001). Three patients required calcium supplementation. LDL cholesterol dropped from 1.75 to 1.2 mmol/L (P < 0.001). Three patients dropped out because of side effects or intolerance of the required dose. CONCLUSION: The results support the feasibility of a larger trial to determine the efficacy of colestipol as a phosphate binder and that other non-proprietary anion-exchange resins may also warrant investigation.
[Mh] Termos MeSH primário: Quelantes/administração & dosagem
Colestipol/administração & dosagem
Falência Renal Crônica/terapia
Fosfatos/sangue
Diálise Renal
[Mh] Termos MeSH secundário: Administração Oral
Biomarcadores/sangue
Coagulação Sanguínea/efeitos dos fármacos
Cálcio/sangue
Quelantes/efeitos adversos
LDL-Colesterol/sangue
Colestipol/efeitos adversos
Estudos de Viabilidade
Seres Humanos
Falência Renal Crônica/sangue
Falência Renal Crônica/diagnóstico
Nova Zelândia
Pacientes Desistentes do Tratamento
Estudos Prospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chelating Agents); 0 (Cholesterol, LDL); 0 (Phosphates); K50N755924 (Colestipol); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150326
[Lr] Data última revisão:
150326
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150106
[St] Status:MEDLINE
[do] DOI:10.1111/nep.12388


  6 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25406854
[Au] Autor:Gonzalez RS; Schwartz DA; Shi C
[Ad] Endereço:Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
[Ti] Título:Colestipol granules in the colon: macroscopic and microscopic findings.
[So] Source:Histopathology;67(1):141-2, 2015 Jul.
[Is] ISSN:1365-2559
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Colestipol/efeitos adversos
Doenças do Colo/etiologia
Hipolipemiantes/efeitos adversos
Mucosa Intestinal/efeitos dos fármacos
[Mh] Termos MeSH secundário: Doenças do Colo/diagnóstico
Colonoscopia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Hypolipidemic Agents); K50N755924 (Colestipol)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:150611
[Lr] Data última revisão:
150611
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141120
[St] Status:MEDLINE
[do] DOI:10.1111/his.12618


  7 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24921636
[Au] Autor:Arnold MA; Swanson BJ; Crowder CD; Frankel WL; Lam-Himlin D; Singhi AD; Stanich PP; Arnold CA
[Ad] Endereço:*Department of Pathology ¶Department of Internal Medicine, Ohio State University Wexner Medical Center †Department of Pathology, Nationwide Children's Hospital, Columbus, OH ‡Department of Pathology, Mercy Medical Center, Des Moines, IA §Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ ∥Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.
[Ti] Título:Colesevelam and colestipol: novel medication resins in the gastrointestinal tract.
[So] Source:Am J Surg Pathol;38(11):1530-7, 2014 Nov.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report the morphologic description of the bile acid sequestrants (BAS) colesevelam and colestipol, as well as the largest series of cholestyramine. Histologically similar medication resins from 4 institutions were prospectively collected over 1 year (26 specimens, 15 patients). Comorbidities included hyperlipidemia (4/15), hypertension (4/15), inflammatory bowel disease (4/15), coronary artery disease (3/15), diarrhea (7/15), hypothyroidism (2/15), and ischemic bowel (1/15). Sites of involvement included the esophagus (1/26), stomach (1/26), small intestine (1/26), ileocecal valve (1/26), and colorectum (22/26). Associated histologic diagnoses included normal (8/26), chronic mucosal injury (11/26), acute inflammation (9/26), erosion/ulceration (6/26), and cytomegalovirus (2/26). The BAS resins were histologically indistinguishable from each other; they were all eosinophilic on hematoxylin and eosin (H&E) and lacked internal "fish-scales." To validate these observations, respective medications were submitted for histologic processing; the processed medications were identical to those in the patient specimens. Rare, irregular "fracture" lines presented diagnostic pitfalls by mimicking the true "fish-scales" of Kayexalate and sevelamer. Clues to the correct identification of BAS include recognition that the "fracture" lines were subtle, irregular, and restricted to large fragments or thick sections, likely representing a processing artifact. Moreover, Kayexalate is violet on H&E and black on acid fast bacillus, and sevelamer characteristically displays a 2-tone color on H&E and is magenta on acid fast bacillus. An association with inflammatory injury was seen (15/26). We believe that the BAS are innocent bystanders in complicated patients, although we cannot exclude their ability to cause mucosal injury in specific settings.
[Mh] Termos MeSH primário: Alilamina/análogos & derivados
Anticolesterolemiantes/análise
Colestipol/análise
Fármacos Gastrointestinais/análise
Intestinos/química
Resinas de Troca Iônica/análise
[Mh] Termos MeSH secundário: Adulto
Idoso
Alilamina/efeitos adversos
Alilamina/análise
Anticolesterolemiantes/efeitos adversos
Biópsia
Resina de Colestiramina/análise
Cloridrato de Colesevelam
Colestipol/efeitos adversos
Feminino
Fármacos Gastrointestinais/efeitos adversos
Seres Humanos
Mucosa Intestinal/química
Mucosa Intestinal/efeitos dos fármacos
Intestinos/efeitos dos fármacos
Resinas de Troca Iônica/efeitos adversos
Masculino
Meia-Idade
Estudos Prospectivos
Medição de Risco
Fatores de Risco
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Gastrointestinal Agents); 0 (Ion Exchange Resins); 11041-12-6 (Cholestyramine Resin); 48G762T011 (Allylamine); K50N755924 (Colestipol); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140613
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000260


  8 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24438965
[Au] Autor:Tishler PV; Rosner B
[Ad] Endereço:Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: peter.tishler@channing.harvard.edu.
[Ti] Título:Treatment of erythropoietic protoporphyria with the oral sorbent colestipol: a proof-of-concept clinical trial.
[So] Source:J Am Acad Dermatol;70(2):391-2, 2014 Feb.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Resinas de Troca de Ânions/administração & dosagem
Colestipol/administração & dosagem
Protoporfiria Eritropoética/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Relação Dose-Resposta a Droga
Esquema de Medicação
Feminino
Seguimentos
Seres Humanos
Protoporfiria Eritropoética/diagnóstico
Índice de Gravidade de Doença
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anion Exchange Resins); K50N755924 (Colestipol)
[Em] Mês de entrada:1403
[Cu] Atualização por classe:140120
[Lr] Data última revisão:
140120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140121
[St] Status:MEDLINE


  9 / 392 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:24199211
[Au] Autor:Barkun AN; Love J; Gould M; Pluta H; Steinhart H
[Ti] Título:Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.
[So] Source:Can J Gastroenterol;27(11):653-9, 2013 Nov.
[Is] ISSN:1916-7237
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bile acid malabsorption (BAM) is a common but frequently under-recognized cause of chronic diarrhea, with an estimated prevalence of 4% to 5%. METHODS: The published literature for the period 1965 to 2012 was examined for articles regarding the pathophysiology and treatment of BAM to provide an overview of the management of BAM in gastroenterology practice. RESULTS: BAM is classified as type 1 (secondary to ileal dysfunction), type 2 (idiopathic) or type 3 (secondary to gastrointestinal disorders not associated with ileal dysfunction). The estimated prevalence of BAM is >90% in patients with resected Crohn disease (CD) and 11% to 52% of unresected CD patients (type 1); 33% in diarrhea-predominant irritable bowel syndrome (type 2); and is a frequent finding postcholecystectomy or postvagotomy (type 3). Investigations include BAM fecal bile acid assay, 23-seleno-25-homo-tauro-cholic acid (SeHCAT) testing and high-performance liquid chromatography of serum 7-α-OH-4-cholesten-3-one (C4), to determine the level of bile acid synthesis. A less time-consuming and expensive alternative in practice is an empirical trial of the bile acid sequestering agent cholestyramine. An estimated 70% to 96% of chronic diarrhea patients with BAM respond to short-course cholestyramine. Adverse effects include constipation, nausea, borborygmi, flatulence, bloating and abdominal pain. Other bile acid sequestering agents, such as colestipol and colesevelam, are currently being investigated for the treatment of BAM-associated diarrhea. CONCLUSIONS: BAM is a common cause of chronic diarrhea presenting in gastroenterology practice. In accordance with current guidelines, an empirical trial of a bile acid sequestering agent is warranted as part of the clinical workup to rule out BAM.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Diarreia/etiologia
Síndromes de Malabsorção/complicações
[Mh] Termos MeSH secundário: Alilamina/análogos & derivados
Alilamina/uso terapêutico
Animais
Resinas de Troca de Ânions/uso terapêutico
Resina de Colestiramina/uso terapêutico
Doença Crônica
Cloridrato de Colesevelam
Colestipol/uso terapêutico
Diarreia/tratamento farmacológico
Seres Humanos
Síndromes de Malabsorção/tratamento farmacológico
Síndromes de Malabsorção/fisiopatologia
Guias de Prática Clínica como Assunto
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anion Exchange Resins); 0 (Bile Acids and Salts); 11041-12-6 (Cholestyramine Resin); 48G762T011 (Allylamine); K50N755924 (Colestipol); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131108
[St] Status:MEDLINE


  10 / 392 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23829947
[Au] Autor:Silva VS; Oliveira L; Gonçalves PP
[Ad] Endereço:CESAM & Departamento de Biologia, Universidade de Aveiro, 3810-193 Aveiro, Portugal. Electronic address: vsilva@ua.pt.
[Ti] Título:Alteration of aluminium inhibition of synaptosomal (Na(+)/K(+))ATPase by colestipol administration.
[So] Source:J Inorg Biochem;128:208-14, 2013 Nov.
[Is] ISSN:1873-3344
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The ability of aluminium to inhibit the (Na(+)/K(+))ATPase activity has been observed by several authors. During chronic dietary exposure to AlCl3, brain (Na(+)/K(+))ATPase activity drops, even if no alterations of catalytic subunit protein expression and of energy charge potential are observed. The aluminium effect on (Na(+)/K(+))ATPase activity seems to implicate the reduction of interacting protomers within the oligomeric ensemble of the membrane-bound (Na(+)/K(+))ATPase. The activity of (Na(+)/K(+))ATPase is altered by the microviscosity of lipid environment. We studied if aluminium inhibitory effect on (Na(+)/K(+))ATPase is modified by alterations in synaptosomal membrane cholesterol content. Adult male Wistar rats were submitted to chronic dietary AlCl3 exposure (0.03 g/day of AlCl3) and/or to colestipol, a hypolidaemic drug (0.31 g/day) during 4 months. The activity of (Na(+)/K(+))ATPase was studied in brain cortex synaptosomes with different cholesterol contents. Additionally, we incubate synaptosomes with methyl-ß-cyclodextrin for both enrichment and depletion of membrane cholesterol content, with or without 300 µM AlCl3. This enzyme activity was significantly reduced by micromolar AlCl3 added in vitro and when aluminium was orally administered to rats. The oral administration of colestipol reduced the cholesterol content and concomitantly inhibited the (Na(+)/K(+))ATPase. The aluminium inhibitory effect on synaptosomal (Na(+)/K(+))ATPase was reduced by cholesterol depletion both in vitro and in vivo.
[Mh] Termos MeSH primário: Alumínio/farmacologia
Colestipol/farmacologia
ATPase Trocadora de Sódio-Potássio/metabolismo
Sinaptossomos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adenosina Trifosfatases/metabolismo
Administração Oral
Alumínio/administração & dosagem
Compostos de Alumínio/administração & dosagem
Compostos de Alumínio/farmacologia
Animais
Encéfalo/efeitos dos fármacos
Encéfalo/enzimologia
Membrana Celular/efeitos dos fármacos
Membrana Celular/metabolismo
Cloretos/administração & dosagem
Cloretos/farmacologia
Colesterol/metabolismo
Colesterol/farmacologia
Colestipol/administração & dosagem
Relação Dose-Resposta a Droga
Hipolipemiantes/administração & dosagem
Hipolipemiantes/farmacologia
Masculino
Ratos
Ratos Wistar
Sinaptossomos/enzimologia
beta-Ciclodextrinas/administração & dosagem
beta-Ciclodextrinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aluminum Compounds); 0 (Chlorides); 0 (Hypolipidemic Agents); 0 (beta-Cyclodextrins); 0 (methyl-beta-cyclodextrin); 3CYT62D3GA (aluminum chloride); 97C5T2UQ7J (Cholesterol); CPD4NFA903 (Aluminum); EC 3.6.1.- (Adenosine Triphosphatases); EC 3.6.3.9 (Sodium-Potassium-Exchanging ATPase); K50N755924 (Colestipol)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130709
[St] Status:MEDLINE



página 1 de 40 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde